Carol E. Peña

2.8k total citations · 1 hit paper
57 papers, 1.5k citations indexed

About

Carol E. Peña is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Carol E. Peña has authored 57 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Molecular Biology, 20 papers in Pulmonary and Respiratory Medicine and 17 papers in Oncology. Recurrent topics in Carol E. Peña's work include Cancer Genomics and Diagnostics (11 papers), Lung Cancer Treatments and Mutations (11 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). Carol E. Peña is often cited by papers focused on Cancer Genomics and Diagnostics (11 papers), Lung Cancer Treatments and Mutations (11 papers) and PI3K/AKT/mTOR signaling in cancer (8 papers). Carol E. Peña collaborates with scholars based in United States, France and Germany. Carol E. Peña's co-authors include Chetan Lathia, Gerold Meinhardt, Michael Shan, Jordi Bruix, Josep M. Llovet, Graham F. Hatfull, Ronald M. Bukowski, Bernard Escudier, Minghua Shan and Marisa L. Pedulla and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Nucleic Acids Research and Nature Medicine.

In The Last Decade

Carol E. Peña

53 papers receiving 1.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma

2012 444 citations Carol E. Peña, Chetan Lathia et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carol E. Peña United States	20	613	445	423	415	401	57	1.5k
Hidetoshi Nitta Japan	27	536 0.9×	266 0.6×	706 1.7×	419 1.0×	757 1.9×	133	2.2k
Narin Voravud Thailand	23	833 1.4×	247 0.6×	700 1.7×	408 1.0×	190 0.5×	65	2.0k
Junichi Uchino Japan	24	285 0.5×	267 0.6×	445 1.1×	262 0.6×	789 2.0×	106	1.9k
Abeer A. Bahnassy Egypt	24	516 0.8×	165 0.4×	501 1.2×	349 0.8×	490 1.2×	89	1.6k
Kouki Nio Japan	16	698 1.1×	86 0.2×	449 1.1×	340 0.8×	427 1.1×	54	1.3k
Hye Seung Han South Korea	27	596 1.0×	734 1.6×	683 1.6×	258 0.6×	72 0.2×	107	2.3k
Hyo‐Suk Lee South Korea	28	338 0.6×	244 0.5×	290 0.7×	270 0.7×	1.8k 4.4×	82	2.4k
Andreas Kaubisch United States	18	498 0.8×	161 0.4×	584 1.4×	129 0.3×	235 0.6×	66	1.3k
Shaohua Lu China	25	1.1k 1.8×	893 2.0×	356 0.8×	993 2.4×	117 0.3×	72	2.2k
Jan‐Erik Frödin Sweden	30	615 1.0×	361 0.8×	1.0k 2.4×	210 0.5×	102 0.3×	84	2.4k

Countries citing papers authored by Carol E. Peña

Since Specialization

Citations

This map shows the geographic impact of Carol E. Peña's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carol E. Peña with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carol E. Peña more than expected).

Fields of papers citing papers by Carol E. Peña

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carol E. Peña. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carol E. Peña. The network helps show where Carol E. Peña may publish in the future.

Co-authorship network of co-authors of Carol E. Peña

This figure shows the co-authorship network connecting the top 25 collaborators of Carol E. Peña. A scholar is included among the top collaborators of Carol E. Peña based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carol E. Peña. Carol E. Peña is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hadd, Andrew G., Jonathan Baden, Fernando Cruz‐Guilloty, et al.. (2025). Establishing a Common Lexicon for Circulating Tumor DNA Analysis and Molecular Residual Disease: Insights From the BLOODPAC Consortium. Clinical and Translational Science. 18(3). e70185–e70185.

Kudo, Masatoshi, Ann‐Lii Cheng, Philippe Merle, et al.. (2024). Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.. Journal of Clinical Oncology. 42(16_suppl). 4109–4109. 1 indexed citations

Quintanilha, Júlia C.F., Susan M. Geyer, Amy S. Etheridge, et al.. (2022). KDR genetic predictor of toxicities induced by sorafenib and regorafenib. The Pharmacogenomics Journal. 22(5-6). 251–257. 5 indexed citations

Quintanilha, Júlia C.F., Alessandro Racioppi, Jin Wang, et al.. (2021). PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors. The Pharmacogenomics Journal. 22(1). 82–88. 6 indexed citations

Lenz, Georg, Eliza A. Hawkes, Gregor Verhoef, et al.. (2020). Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 34(8). 2184–2197. 52 indexed citations

Ramanathan, Ramesh K., Daniel D. Von Hoff, Ferry A.L.M. Eskens, et al.. (2020). Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced Cancer. Targeted Oncology. 15(2). 163–174. 39 indexed citations

Brose, Marcia S., et al.. (2019). Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated Thyroid Cancer: Subanalysis of the Sorafenib Phase III DECISION Trial. Clinical Cancer Research. 25(24). 7370–7380. 14 indexed citations

Capdevila, Jaume, Ignacio Matos, Francesco M. Mancuso, et al.. (2019). Identification of Expression Profiles Defining Distinct Prognostic Subsets of Radioactive-Iodine Refractory Differentiated Thyroid Cancer from the DECISION Trial. Molecular Cancer Therapeutics. 19(1). 312–317. 10 indexed citations

Crona, Daniel J., Andrew D. Skol, Veli‐Matti Leppänen, et al.. (2018). Genetic Variants of VEGFA and FLT4 Are Determinants of Survival in Renal Cell Carcinoma Patients Treated with Sorafenib. Cancer Research. 79(1). 231–241. 25 indexed citations

10.

Alberts, Steven R., Carol E. Peña, Isabelle Genvresse, et al.. (2018). Phase I dose-escalation study of copanlisib in combination with gemcitabine or cisplatin plus gemcitabine in patients with advanced cancer. British Journal of Cancer. 118(4). 462–470. 34 indexed citations

11.

Zhu, Andrew X., Yoon‐Koo Kang, Olivier Rosmorduc, et al.. (2016). Biomarker Analyses of Clinical Outcomes in Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib with or without Erlotinib in the SEARCH Trial. Clinical Cancer Research. 22(19). 4870–4879. 22 indexed citations

12.

Rudolph, Marion, Tobias Anzeneder, Georg Beckmann, et al.. (2016). AKT1 E17K mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection. BMC Cancer. 16(1). 622–622. 66 indexed citations

13.

Lazar, Vladimir, Nathalie Lassau, Guillaume Meurice, et al.. (2013). Sorafenib plus dacarbazine in solid tumors: a phase I study with dynamic contrast-enhanced ultrasonography and genomic analysis of sequential tumor biopsy samples. Investigational New Drugs. 32(2). 312–322. 4 indexed citations

14.

Herrera, David, et al.. (2010). Mucositis in irradiated cancer patients: Effects of an antiseptic mouthrinse. Medicina oral, patología oral y cirugía bucal. 15(5). e732–e738. 25 indexed citations

15.

Beekman, Johanna M., Joachim Reischl, David Henderson, et al.. (2008). Recovery of microarray-quality RNA from frozen EDTA blood samples. Journal of Pharmacological and Toxicological Methods. 59(1). 44–49. 28 indexed citations

16.

Mesri, Mehdi, Glennda Smithson, Andrei I. Chapoval, et al.. (2006). Inhibition of in vitro and in vivo T cell responses by recombinant human Tim-1 extracellular domain proteins. International Immunology. 18(3). 473–484. 20 indexed citations

17.

Hitt, Ricardo, Antonio Jimeno, María Rodríguez‐Pinilla, et al.. (2004). Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. British Journal of Cancer. 91(12). 2005–2011. 23 indexed citations

18.

Peña, Carol E., et al.. (1998). Mycobacteriophage D29 integrase-mediated recombination: specificity of mycobacteriophage integration. Gene. 225(1-2). 143–151. 16 indexed citations

19.

Peña, Carol E.. (1998). The role of supercoiling in mycobacteriophage L5 integrative recombination. Nucleic Acids Research. 26(17). 4012–4018. 15 indexed citations

20.

Peña, Carol E., et al.. (1997). Characterization of the mycobacteriophage L5 attachment site, attP 1 1 Edited by M. Gottesman. Journal of Molecular Biology. 266(1). 76–92. 50 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact